Atrial Fibrillation Catheter Ablation, BTKi-induced Atrial Fibrillation, Hematologic Malignancy
Conditions
Keywords
atrial fibrillation, Bruton tyrosine kinase inhibitors, catheter ablation,, atrial fibrillation recurrence
Brief summary
Targeted anticancer drugs have completely changed the prognosis of malignancies during the past decades. Patients suffering from malignancies live longer and this allows adverse events of anticancer drugs to emerge, notably cardiovascular adverse events. It is particularly important because of the great morbimortality of major cardiovascular events like myocardial infarction or stroke and because of their frequency in cancer populations. Indeed, cardiovascular death is the second cause of deaths after malignancy itself in this population. Atrial fibrillation (AF) is a non rare cardiovascular adverse events associated with a shorter overall survival in some malignancies localization. The emblematic anticancer drugs promoting AF is ibrutinib belonging to the Bruton tyrosine kinase inhibitors (BTKi), which are indicated in hematological malignancies. Incidence of AF with ibrutinib is estimated to 4.92/100 person-years; 95% CI: 2.91-4.81 but is underestimated because of the absence of systematic electrocardiogram recording. The management of AF rests on anticoagulation if indicated by the CHA2DS2-VASc score, and on the choice between a rate or rhythm control strategy. Rate control is the privileged strategy because of the risk of drugs interactions of the anti-arrhythmic drugs in a context of anticancer drugs co-prescriptions. But in case of symptoms with normal heart rate, life expectancy counted in years and preserved condition, catheter ablation has to be discussed. Whereas this interventional procedure has been greatly studied in the general population, no study exists in patients with hematological malignancies. The investigators aim to describe baseline characteristics of a population of BTKi-induced AF undergone AF catheter ablation.
Detailed description
Targeted anticancer drugs have completely changed the prognosis of malignancies during the past decades. Patients suffering from malignancies live longer and this allows adverse events of anticancer drugs to emerge, notably cardiovascular adverse events. It is particularly important because of the great morbimortality of major cardiovascular events like myocardial infarction or stroke and because of their frequency in cancer populations. Indeed, cardiovascular death is the second cause of deaths after malignancy itself in this population. Atrial fibrillation (AF) is a non rare cardiovascular adverse events associated with a shorter overall survival in some malignancies localization. The emblematic anticancer drugs promoting AF is ibrutinib belonging to the Bruton tyrosine kinase inhibitors (BTKi), which are indicated in hematological malignancies. Incidence of AF with ibrutinib is estimated to 4.92/100 person-years; 95% CI: 2.91-4.81 but is underestimated because of the absence of systematic electrocardiogram recording. The management of AF rests on anticoagulation if indicated by the CHA2DS2-VASc score, and on the choice between a rate or rhythm control strategy. Rate control is the privileged strategy because of the risk of drugs interactions of the anti-arrhythmic drugs in a context of anticancer drugs co-prescriptions. But in case of symptoms with normal heart rate, life expectancy counted in years and preserved condition, catheter ablation has to be discussed. Whereas this interventional procedure has been greatly studied in the general population, no study exists in patients with hematological malignancies. The investigators aim to describe baseline characteristics of a population of BTKi-induced AF undergone AF catheter ablation.
Interventions
PROCEDUREAtrial fibrillation catheter ablation in a population of BTKi-induced atrial fibrillation
Atrial fibrillation catheter ablation in a population of BTKi-induced atrial fibrillation
Sponsors
University Hospital, Caen
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* every adult patient treated by BTKi for a hematological malignancy * with a new onset recurrence of AF occurring after BTKi initiation and treated by catheter ablation * with an available 12 months follow up after catheter ablation
Exclusion criteria
* Patients younger than 18 years old * Severe mitral regurgitation/stenosis or rhumatismal heart disease whatever the grade * Permanent AF * Patient who had AF rhythm during the first administration of BTKi
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Description of the one-year AF recurrence rate after catheter ablation in a population of BTKi induced AF | 1 year follow-up from the catheter ablation date | AF recurrence is defined as atrial fibrillation or atrial tachycardia or atrial flutter, on a single 12-lead ECG or lasting more than 30 seconds on Holter monitoring in the period between the end of the 3-month blanking period and 12-month follow-up. |
Secondary
| Measure | Time frame |
|---|---|
| Description of the baseline characteristic of the population of BTKi induced AF with AF catheter ablation carried out | At inclusion (= the time of ablation date) |
| Description of atrial electrophysiological properties during AF catheter ablation in a population of BTKi induced AF | At inclusion (= the time of ablation date) |
| Description of AF catheter ablation complications at 3 months follow-up in a population of BTKi induced AF (MACE, sepsis, bleeding, hospitalization prolongation, hospitalization readmission, mortality) | 3 months follow-up from the ablation date |
| Identification of baseline parameters and electrophysiologic parameters associated with AF recurrence at 12 months follow-up | 1 year follow-up from the catheter ablation date |
Countries
France
Contacts
Primary ContactJoachim ALEXANDRE, MD, PhD
Outcome results
None listed